Fig. 4: Predictors of anti-SARS-CoV-2 spike antibody and T cell responses after two doses of COVID-19 vaccine. | Nature Medicine

Fig. 4: Predictors of anti-SARS-CoV-2 spike antibody and T cell responses after two doses of COVID-19 vaccine.

From: SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Fig. 4

Forest plot of multivariable logistic regression model fitted on post-V2 anti-SARS-CoV-2 RBD-binding total Ig antibody (whole group 1 and group 2 (n = 2,204) and matched healthy controls (n = 225)) (a) and IFNγ T cell responses (group 1 (n = 645) and matched healthy controls (n = 189)) (b). OR of anti-SARS-CoV-2 RBD-binding total Ig >380 AU ml−1 (a) and OR of anti-SARS-CoV-2 spike IFNγ T cell response ≥4 SFCs per 106 PBMCs (b). Center of error bars represents OR, and whiskers represent 95% CI. P values are outputs of multivariable logistic regression model. P < 0.05 is significant and marked with blue lines. AAV, ANCA-associated vasculitis; CD, Crohn’s disease; DMARDs, disease-modifying anti-rheumatic drugs; HD, hemodialysis; HD on IS, hemodialysis on immunosuppression; HM, hematological malignancy; IA, inflammatory arthritis; L-AI, autoimmune hepatitis; L-Cir, liver cirrhosis; L-Tr, liver transplant; OSFC, zero spot forming cells; SC, solid cancer; UC, ulcerative colitis; wks, weeks.

Back to article page